SCHEMBL1428084

SCHEMBL1428084

Fc1ccc(-c2nc3ccc(Cl)cn3c2CNc2nccc(C3CCCN3)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 1/20 0.43
SLC2A1 P11166 4/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
PRKCG P05129 1/20 0.41
FGFR1 P11362 1/20 0.41
MAPK1 P28482 1/20 0.41
FLT4 P35916 1/20 0.41
FRK P42685 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CSNK1G2 P78368 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
MINK1 Q8N4C8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428065 0.81 SIRT5 (0.53) SIRT5SLC2A1MEN1KMT2ASLC2A3
SCHEMBL1427447 0.79 SIRT5 (0.55) SIRT5SLC2A1MEN1KMT2ASLC2A3
SCHEMBL1428226 0.77 SLC2A1 (0.58) SIRT5SLC2A1MEN1KMT2ASLC2A3
SCHEMBL1427668 0.77 SIRT5 (0.48) SIRT5SLC2A1MEN1KMT2ASLC2A3
SCHEMBL1430216 0.76 ALOX5 (0.44) SIRT5SLC2A1MEN1KMT2ASLC2A3
SCHEMBL1430197 0.76 SIRT5 (0.42) SIRT5SLC2A1MEN1KMT2APRKD3
SCHEMBL1430188 0.74 SIRT5 (0.43) SIRT5SLC2A1MEN1KMT2APRKD3
SCHEMBL1430914 0.74 SIRT5 (0.43) SIRT5SLC2A1MEN1KMT2APRKD3
SCHEMBL1430189 0.74 SIRT5 (0.43) SIRT5SLC2A1MEN1KMT2APRKD3
SCHEMBL1430096 0.74 SIRT5 (0.56) SIRT5SLC2A1MEN1KMT2ASLC2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
EP-2300470-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS Sepracor Inc. (US) 2011-03-30 EP disclosed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SIRT5 379/4885SLC2A1 2033/4885MEN1 1720/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SIRT5 379/4885SLC2A1 2033/4885MEN1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.